Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

IDYA - Ideaya Biosciences Inc


IEX Last Trade
39.48
0.310   0.785%

Share volume: 379,125
Last Updated: Fri 30 Aug 2024 09:59:59 PM CEST
Research and Development in Biotechnology (except Nanobiotechnology): 0.21%

PREVIOUS CLOSE
CHG
CHG%

$39.17
0.31
0.79%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Fundamental analysis
8%
Profitability 0%
Dept financing 2%
Liquidity 75%
Performance 0%
Company vs Stock growth
vs
Performance
5 Days
0.03%
1 Month
-6.51%
3 Months
10.37%
6 Months
-11.38%
1 Year
35.69%
2 Year
310.60%
Key data
Stock price
$39.48
P/E Ratio 
-21.71
DAY RANGE
N/A - N/A
EPS 
-$2.21
52 WEEK RANGE
$23.41 - $47.74
52 WEEK CHANGE
$0.33
MARKET CAP 
3.337 B
YIELD 
N/A
SHARES OUTSTANDING 
84.481 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/05/2024
BETA 
1.56
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$317,101
AVERAGE 30 VOLUME 
$515,601
Company detail
CEO: Yujiro Hata
Region: US
Website: https://www.ideayabio.com/
Employees: 102
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services

ideaya biosciences is an oncology-focused biotechnology company committed to the discovery of personalized synthetic lethality medicines targeting dna damage and repair for genetically defined patient populations and immuno-oncology therapies targeting the tumor microenvironment. founded in 2015, ideaya’s investors include 5am ventures (5am), canaan partners (canaan), celgene, wuxi healthcare ventures (wuxi), novartis institute of biomedical research, and alexandria real estate. the company has assembled a world-class drug discovery team and scientific advisory board (sab) that is represented by a nobel laureate and three members of the national academy of sciences. ideaya is located in south san francisco and la jolla, california.

Recent news